William Blair Issues Pessimistic Estimate for BMY Earnings

Bristol Myers Squibb Company (NYSE:BMY) – Research analysts at William Blair cut their Q1 2026 earnings estimates for shares of Bristol Myers Squibb in a note issued to investors on Friday, October 31st. William Blair analyst M. Phipps now forecasts that the biopharmaceutical company will post earnings of $1.61 per share for the quarter, down from their prior estimate of $1.63. The consensus estimate for Bristol Myers Squibb’s current full-year earnings is $6.74 per share. William Blair also issued estimates for Bristol Myers Squibb’s Q2 2026 earnings at $1.55 EPS, Q3 2026 earnings at $1.46 EPS, Q4 2026 earnings at $1.47 EPS, FY2026 earnings at $6.10 EPS, FY2027 earnings at $6.14 EPS and FY2028 earnings at $5.39 EPS.

A number of other brokerages have also recently issued reports on BMY. Citigroup restated a “neutral” rating on shares of Bristol Myers Squibb in a report on Monday, October 13th. Weiss Ratings reissued a “hold (c-)” rating on shares of Bristol Myers Squibb in a report on Tuesday, October 14th. Sanford C. Bernstein reissued a “market perform” rating on shares of Bristol Myers Squibb in a research note on Monday. Daiwa America cut Bristol Myers Squibb from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, August 5th. Finally, Morgan Stanley reissued a “hold” rating on shares of Bristol Myers Squibb in a research note on Thursday, July 31st. One analyst has rated the stock with a Strong Buy rating, five have given a Buy rating and fifteen have issued a Hold rating to the company’s stock. According to data from MarketBeat, the company currently has an average rating of “Hold” and an average target price of $57.23.

Bristol Myers Squibb Price Performance

Bristol Myers Squibb stock opened at $45.58 on Monday. The firm has a market capitalization of $92.78 billion, a P/E ratio of 18.38, a PEG ratio of 2.23 and a beta of 0.33. Bristol Myers Squibb has a 1 year low of $42.52 and a 1 year high of $63.33. The business has a 50-day moving average of $45.28 and a 200-day moving average of $46.73. The company has a current ratio of 1.21, a quick ratio of 1.11 and a debt-to-equity ratio of 2.54.

Bristol Myers Squibb (NYSE:BMY) last announced its quarterly earnings data on Thursday, October 30th. The biopharmaceutical company reported $1.63 EPS for the quarter, topping analysts’ consensus estimates of $1.52 by $0.11. Bristol Myers Squibb had a return on equity of 80.04% and a net margin of 10.58%.The business had revenue of $12.22 billion during the quarter, compared to analysts’ expectations of $11.75 billion. During the same period in the previous year, the firm earned $1.80 earnings per share. The firm’s quarterly revenue was up 2.8% compared to the same quarter last year. Bristol Myers Squibb has set its FY 2025 guidance at 6.400-6.600 EPS.

Bristol Myers Squibb Dividend Announcement

The company also recently disclosed a quarterly dividend, which was paid on Monday, November 3rd. Stockholders of record on Friday, October 3rd were given a dividend of $0.62 per share. This represents a $2.48 annualized dividend and a dividend yield of 5.4%. The ex-dividend date of this dividend was Friday, October 3rd. Bristol Myers Squibb’s dividend payout ratio is currently 83.78%.

Insider Buying and Selling at Bristol Myers Squibb

In other news, EVP David V. Elkins sold 56,000 shares of the company’s stock in a transaction dated Tuesday, September 2nd. The stock was sold at an average price of $47.33, for a total transaction of $2,650,480.00. Following the completion of the transaction, the executive vice president directly owned 167,379 shares of the company’s stock, valued at $7,922,048.07. This represents a 25.07% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. 0.09% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Bristol Myers Squibb

A number of large investors have recently bought and sold shares of BMY. Vanguard Group Inc. boosted its holdings in Bristol Myers Squibb by 1.8% during the second quarter. Vanguard Group Inc. now owns 194,925,206 shares of the biopharmaceutical company’s stock worth $9,023,088,000 after purchasing an additional 3,522,202 shares during the last quarter. Charles Schwab Investment Management Inc. boosted its stake in shares of Bristol Myers Squibb by 16.8% during the 2nd quarter. Charles Schwab Investment Management Inc. now owns 70,802,680 shares of the biopharmaceutical company’s stock worth $3,277,456,000 after buying an additional 10,195,775 shares during the last quarter. Geode Capital Management LLC boosted its stake in shares of Bristol Myers Squibb by 1.6% during the 2nd quarter. Geode Capital Management LLC now owns 46,176,690 shares of the biopharmaceutical company’s stock worth $2,132,976,000 after buying an additional 723,459 shares during the last quarter. Norges Bank acquired a new position in shares of Bristol Myers Squibb during the 2nd quarter worth about $1,554,154,000. Finally, Ameriprise Financial Inc. boosted its position in Bristol Myers Squibb by 1.3% during the second quarter. Ameriprise Financial Inc. now owns 32,579,618 shares of the biopharmaceutical company’s stock valued at $1,508,099,000 after purchasing an additional 432,158 shares during the last quarter. Institutional investors and hedge funds own 76.41% of the company’s stock.

About Bristol Myers Squibb

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.